Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome

Barbara Chubak, Brandie Heald, Richard R Sharp

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: Routine microsatellite instability and immunohistochemistry screening of colorectal cancers can assist in identifying a significant proportion of cancers attributable to Lynch syndrome. This article considers whether it is necessary to obtain patient informed consent for microsatellite instability and immunohistochemistry screening. Results: Although microsatellite instability screening examines genetic features of a tumor, it lacks several important characteristics that typically mandate formal informed consent to genetic testing. Microsatellite instability screening describes discrete tissue samples and does not provide information about the rest of the patient's body or germline. In contrast, immunohistochemistry screening is a proteomic test that may reveal information about the patient's germline. As such, immunohistochemistry screening can be viewed as similar to other forms of genetic testing, in which explicit patient consent is regarded as an ethical prerequisite. Conclusion: There is no ethical requirement to obtain explicit informed consent for microsatellite instability screening of colorectal tumor samples for Lynch syndrome. There is support for obtaining patient consent to immunohistochemistry testing, given its similarities with other genetic analyses for which informed consent is typically deemed necessary. Regardless of which screening test is used, it is important to prepare patients and their families for the possibility of a positive screening test.

Original languageEnglish (US)
Pages (from-to)356-360
Number of pages5
JournalGenetics in Medicine
Volume13
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Microsatellite Instability
Informed Consent
Immunohistochemistry
Genetic Testing
Colorectal Neoplasms
Proteomics
Neoplasms

Keywords

  • colorectal cancer
  • ethics
  • HNPCC
  • IHC screening
  • informed consent
  • Lynch syndrome
  • MSI screening

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. / Chubak, Barbara; Heald, Brandie; Sharp, Richard R.

In: Genetics in Medicine, Vol. 13, No. 4, 04.2011, p. 356-360.

Research output: Contribution to journalArticle

@article{c3d7893288e542068a4427bea9314cea,
title = "Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome",
abstract = "Objective: Routine microsatellite instability and immunohistochemistry screening of colorectal cancers can assist in identifying a significant proportion of cancers attributable to Lynch syndrome. This article considers whether it is necessary to obtain patient informed consent for microsatellite instability and immunohistochemistry screening. Results: Although microsatellite instability screening examines genetic features of a tumor, it lacks several important characteristics that typically mandate formal informed consent to genetic testing. Microsatellite instability screening describes discrete tissue samples and does not provide information about the rest of the patient's body or germline. In contrast, immunohistochemistry screening is a proteomic test that may reveal information about the patient's germline. As such, immunohistochemistry screening can be viewed as similar to other forms of genetic testing, in which explicit patient consent is regarded as an ethical prerequisite. Conclusion: There is no ethical requirement to obtain explicit informed consent for microsatellite instability screening of colorectal tumor samples for Lynch syndrome. There is support for obtaining patient consent to immunohistochemistry testing, given its similarities with other genetic analyses for which informed consent is typically deemed necessary. Regardless of which screening test is used, it is important to prepare patients and their families for the possibility of a positive screening test.",
keywords = "colorectal cancer, ethics, HNPCC, IHC screening, informed consent, Lynch syndrome, MSI screening",
author = "Barbara Chubak and Brandie Heald and Sharp, {Richard R}",
year = "2011",
month = "4",
doi = "10.1097/GIM.0b013e31820aee09",
language = "English (US)",
volume = "13",
pages = "356--360",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome

AU - Chubak, Barbara

AU - Heald, Brandie

AU - Sharp, Richard R

PY - 2011/4

Y1 - 2011/4

N2 - Objective: Routine microsatellite instability and immunohistochemistry screening of colorectal cancers can assist in identifying a significant proportion of cancers attributable to Lynch syndrome. This article considers whether it is necessary to obtain patient informed consent for microsatellite instability and immunohistochemistry screening. Results: Although microsatellite instability screening examines genetic features of a tumor, it lacks several important characteristics that typically mandate formal informed consent to genetic testing. Microsatellite instability screening describes discrete tissue samples and does not provide information about the rest of the patient's body or germline. In contrast, immunohistochemistry screening is a proteomic test that may reveal information about the patient's germline. As such, immunohistochemistry screening can be viewed as similar to other forms of genetic testing, in which explicit patient consent is regarded as an ethical prerequisite. Conclusion: There is no ethical requirement to obtain explicit informed consent for microsatellite instability screening of colorectal tumor samples for Lynch syndrome. There is support for obtaining patient consent to immunohistochemistry testing, given its similarities with other genetic analyses for which informed consent is typically deemed necessary. Regardless of which screening test is used, it is important to prepare patients and their families for the possibility of a positive screening test.

AB - Objective: Routine microsatellite instability and immunohistochemistry screening of colorectal cancers can assist in identifying a significant proportion of cancers attributable to Lynch syndrome. This article considers whether it is necessary to obtain patient informed consent for microsatellite instability and immunohistochemistry screening. Results: Although microsatellite instability screening examines genetic features of a tumor, it lacks several important characteristics that typically mandate formal informed consent to genetic testing. Microsatellite instability screening describes discrete tissue samples and does not provide information about the rest of the patient's body or germline. In contrast, immunohistochemistry screening is a proteomic test that may reveal information about the patient's germline. As such, immunohistochemistry screening can be viewed as similar to other forms of genetic testing, in which explicit patient consent is regarded as an ethical prerequisite. Conclusion: There is no ethical requirement to obtain explicit informed consent for microsatellite instability screening of colorectal tumor samples for Lynch syndrome. There is support for obtaining patient consent to immunohistochemistry testing, given its similarities with other genetic analyses for which informed consent is typically deemed necessary. Regardless of which screening test is used, it is important to prepare patients and their families for the possibility of a positive screening test.

KW - colorectal cancer

KW - ethics

KW - HNPCC

KW - IHC screening

KW - informed consent

KW - Lynch syndrome

KW - MSI screening

UR - http://www.scopus.com/inward/record.url?scp=79954993020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954993020&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e31820aee09

DO - 10.1097/GIM.0b013e31820aee09

M3 - Article

VL - 13

SP - 356

EP - 360

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 4

ER -